Latest news with #MikeKelly
Politico
4 days ago
- Business
- Politico
Chamber drops six figures on megabill ads
With Daniel Lippman AIR COVER: The U.S. Chamber of Commerce is rolling out a six-figure ad blitz to provide backup for key Republican lawmakers for their support of the House-passed reconciliation package — and knocking several Democratic frontliners for their votes against the bill. — The business lobby is going up with billboards and digital ads thanking 10 House Republicans for voting last week to extend the 2017 tax cuts: Pennsylvania's Mike Kelly, Oklahoma's Stephanie Bice, Ohio's Mike Carey, Utah's Blake Moore, Indiana's Rudy Yakym, South Dakota's Dusty Johnson, California's Davd Valadao, Michigan's Lisa McClain and Arkansas' French Hill and Bruce Westerman. — The campaign will also include ads preemptively thanking Senate Finance Chair Mike Crapo (R-Idaho) and Senate Environment and Public Works Chair Shelley Moore Capito ( for their support of the bill. — On the flip side, the Chamber is cutting ads going after a handful of House Democrats in battleground seats for voting against the bill, which the Chamber's ads argue is tantamount to supporting 'the largest tax increase in American history.' Those spots will run in the districts of Reps. Marcy Kaptur and Emilia Sykes of Ohio, Gabe Vasquez of New Mexico and Derek Tran of California, according to a spokesperson. — The ad buy reiterates messaging from the reconciliation bill's supporters that will surely continue through next year's midterms. It is meant to counter the deluge of ads that are already hitting Republican lawmakers over the reconciliation bill's cuts to programs like Medicaid. In addition to the Chamber, which has also been holding events with local affiliates and GOP lawmakers in their districts, groups like the Business Roundtable and Americans for Prosperity have dropped millions in ad support for the package. — 'There is a lot of misinformation being spread about this legislation,' Chamber senior political strategist Ashlee Rich Stephenson said in a statement. Extending the 2017 tax cuts is one of — if not the — top policy priorities for business groups like the Chamber, which said the ad blitz is likely to expand and is aimed at 'educat[ing] the public on why the bill is good for the economy and for creating more jobs with higher wages,' even as deficit hawks on the right call for steeper spending cuts. TGIF and welcome to PI. What's going on out there? You can add me on Signal, email me at coprysko@ and be sure to follow me on X: @caitlinoprysko. BURR LOBBYING FOR TOBACCO COALITION: Former Sen. Richard Burr (R-N.C.) has continued to add new lobbying clients since his cooling-off period to lobby the Hill ended at the beginning of the year. — Among the newest clients for the former ranking member of the Senate HELP Committee is the Coalition for Smarter Regulation of Nicotine. Though the group has a barebones online presence, lobbying disclosures show it is backed by tobacco giants Altria, Japan Tobacco International, Reynolds American and Reynolds parent company British American Tobacco. — Burr and a pair of former staffers who have joined him at DLA Piper began lobbying last month on FDA regulation and enforcement policy on behalf of the coalition, according to a disclosure filing. — A spokesperson for the coalition, whose members also sell e-cigarettes, told PI that the group's aim is 'to advocate for urgent reform of FDA regulation of tobacco and nicotine products, in the face of a mass-scale illicit market crisis.' — Cheap, black market vape products have flooded into the U.S. from China in recent years, cutting into sales of FDA-approved products and triggering calls from the tobacco and vape industries alike for a crackdown on illicit vapes, as well as an overhaul of the FDA process for approving and bringing more new products to market — objectives the coalition spokesperson echoed. CHIP SHOT: 'Since the start of this year, Nvidia CEO Jensen Huang has been thrust into an unexpected new role — chief lobbyist for his company — forcing him to carry its hopes, suggestions and pleas directly to President Donald Trump,' The Information's Qianer Liu and Wayne Ma report. — 'Many of Huang's conversations with Trump have happened at Mar-a-Lago, Trump's residence and private club in south Florida, and Huang has made far more visits there than have been publicly reported, according to a person with direct knowledge of the matter.' — 'Indeed, these tête-à-têtes in Palm Beach have become frequent enough for one Nvidia executive to remark on Huang's absence from the company's Santa Clara, Calif., headquarters 'We see a lot less of Jensen,' the executive said. 'He's traveling to Florida a lot.'' — 'Huang's direct approach to dealing with Trump is a marked break from the past, when Huang generally left it to his lieutenants — and his lieutenants' lieutenants — to handle the company's relationships with the U.S. government. Generally, they engaged in traditional lobbying efforts, speaking regularly to bureaucrats and policymakers in an effort to shape public policy that favored Nvidia.' FORMER FDA POLICY CHIEF RETURNING TO K STREET: Kim Trzeciak, who served as the FDA's deputy commissioner for policy, legislation, and international affairs during the Biden administration, has joined Capitol Hill Consulting Group as a senior vice president. — Trzeciak joined the FDA in 2022 as its top policy official, where she oversaw the agency's policy and legislative strategy and led engagement with Congress and the rest of the federal government as well as state, local and tribal governments and international partners. — She previously worked on the Hill as a top aide on the House Energy and Commerce Health Subcommittee and for the late Rep. John Dingell (D-Mich.), with stints at Glover Park Group (now FGS Global) and as an in-house lobbyist at Mylan in between. — Trzeciak will be registering to lobby at CHCG, which represents a number of health care clients like Purdue Pharma, generic drugmaker Teva, Cigna, the Association for Accessible Medicines and dialysis giant Davita. WHISKEY TANGO FOXTROT: 'Federal authorities are investigating a clandestine effort to impersonate White House chief of staff Susie Wiles ... after an unknown individual reached out to prominent Republicans and business executives pretending to be her,' people familiar with the matter tell The Wall Street Journal's Josh Dawsey. — 'In recent weeks, senators, governors, top U.S. business executives and other well-known figures have received text messages and phone calls from a person who claimed to be the chief of staff, the people familiar with the messages said.' — 'But the messages weren't from Wiles—and the Federal Bureau of Investigation and the White House are trying to figure out who is behind the effort and what the goal is, according to some of the people. FBI officials have told the White House they don't believe a foreign nation is involved, some of the people said.' — Wiles, who 'is widely viewed as President Trump's closest adviser' and 'has a deep bench of contacts in Republican circles,' reportedly 'told associates that her [personal] cellphone contacts were hacked, according to some of the people, giving the impersonator access to the private phone numbers of some of the country's most influential people.' Jobs report — Molly Fromm is now vice president and general counsel at the Nickles Group. She previously was general counsel and parliamentarian for House Ways and Means Chair Jason Smith (R-Mo.). — Growth Energy has added Jared Henderson and Emma Keiser as directors of government affairs. Henderson was most recently a senior policy adviser for Sen. Ben Ray Luján (D-N.M.) and Keiser was most recently a legislative assistant for Sen. Joni Ernst (R-Iowa). — Sam Alleman is now director of coalitions for the Human Rights Campaign. He previously was national LGBTQ+ engagement director for the Harris campaign and is a DNC and Planned Parenthood Action Fund alum. — Prominent conservative attorney Kannon Shanmugam is joining the Harvard Corporation. He's a partner at Paul, Weiss, Rifkind, Wharton & Garrison and is a George W. Bush DOJ alum. — Matthew Creegan will be director of media relations at General Motors. He previously was head of executive comms at the Ford Foundation. — Gautam Raghavan is now a partner in the nonprofit and social impact practice at True Search. He previously was director of presidential personnel in the Biden White House. — Jordan Brewer is joining the State Department's Bureau of Cyberspace and Digital Policy as a special adviser. Brewer was previously manager of government affairs at the Cato Institute. — Josué Estrada is now COO at the Center for AI Safety. Estrada was previously chief operating officer at both Salesforce and the Chan Zuckerberg Initiative. — Alyssa Penna is now director of federal policy at United States of Care. She most recently was an analyst at CMS' Office of Legislation. — Jenna Sumar and Kevin Lowery are launching a creative studio, Collection Media. Sumar previously was chief official videographer for the Biden White House. Lowery previously was creative director at Weymouth Watson and is a Stacey Abrams alum. — Cambridge Global Advisors has added Patrick Lechleitner, Elaine Duke, Katie Tobin, Ryan Scudder, Paul Thomas, Tim Devine and Morgan Ryan. — Cindy Dyer is now chief program officer at the McCain Institute. She most recently was U.S. ambassador-at-large to monitor and combat trafficking in persons. New Joint Fundraisers MARSHALL VICTORY FUND (Steve Marshall for Senate, Fighting for Alabama PAC) New PACs ALABAMA CONSERVATIVES (Super PAC) ALABAMA STRONG PAC (Super PAC) AMERICAN MADE AND POWERED (Super PAC) BRINGING VIRGINIA BACK PAC (Super PAC) Dems 2025 (Hybrid PAC) FIGHTING FOR ALABAMA PAC (Leadership PAC: Steven T Marshall) Justice Unites Liberty, Integrity, and America PAC (Leadership PAC: Julia Hashemieh) NESTPOINT PAC (PAC) Power of the People (PAC) United States Working Class Republican Caucus (Hybrid PAC) New Lobbying REGISTRATIONS Continental Strategy, LLC: Avangrid Continental Strategy, LLC: Lkq Corporation Cornerstone Government Affairs, Inc.: National Disability Rights Network Dlg Partners (Fka Dragon List Global): White Star Capital USA Inc. Dutko Worldwide, LLC: Pattern Inc. Fgs Global (US) LLC (Fka Fgh Holdings LLC): Johns Hopkins University Fgs Global (US) LLC (Fka Fgh Holdings LLC): Sidley Austin LLP (On Behalf Of Hewlett Packard Enterprise Co.) Foxhound Advisors: Bell Geospace Foxhound Advisors: Medexpert Goodrx, Inc.: Goodrx, Inc. Icebreaker Strategies, LLC: Community Development Foundation Porterfield, Fettig & Sears, LLC: General Catalyst Group Management, LLC S-3 Group: Oshkosh Corporation Snyder Gressard Strategy: Alaska Wilderness League Snyder Gressard Strategy: League Of Conservation Voters Snyder Gressard Strategy: Oceana Snyder Gressard Strategy: Tides Center Theyfeartruth Federal Government Of America: Theyfeartruth Federal Government Of America Tusk Strategies, LLC: Somos Healthcare Providers, Inc. New Lobbying Terminations Venable LLP: It'S Electric Inc. Venable LLP: Newrange Copper Nickel LLC
Yahoo
7 days ago
- General
- Yahoo
NJ students will be able to visit 9/11 Memorial & Museum for free, Murphy announces
New Jersey schools will be able to send students on field trips to the 9/11 Memorial & Museum in lower Manhattan thanks to a public-private initiative. The program will fund both in-person and virtual field trips as part of a collaboration among the state, the museum and the Wilf Family Foundations. The new public-private initiative will fund student visits to the museum at no cost in an effort to expand access to 9/11 education. There will be self-guided school visits for students in grades three to 12 to help teachers engage them in age-appropriate lessons about the historical significance of 9/11, the stories of those who were killed, the heroism of those who responded and rebuilt, and the values of resilience, empathy and civic responsibility. Mike Kelly: Why can't we really confront Saudi support of the 9/11 attacks? Will we ever? 'The September 11, 2001 terrorist attacks left a profound mark on New Jersey families, and the memory of that painful day remains as important as ever,' Gov. Phil Murphy said in a statement. 'For so many of us — whether we watched on television, from across the Hudson River, or the streets of lower Manhattan — we will never forget the events of 9/11. Now, there is a whole generation for whom 9/11 is just images on TV or in a history book. These field trips will ensure our students understand what happened on 9/11 and its connection to our communities, helping them to navigate the challenges of today's world with knowledge and empathy.' New companion resources created with support from the Wilf Family Foundations will complement the experience. 'The effects of 9/11 reached far beyond New York City, impacting families across New Jersey and the tri-state area,' said Zygi Wilf of the foundation. 'We are proud to support helping New Jersey students experience the museum for free so that a new generation can understand the history and never forget the lessons of that day, helping to preserve the memory of those killed while fostering a deeper understanding of our shared past.' It is unclear whether the program will include transportation expenses for schools interested in visiting the museum. Katie Sobko covers the New Jersey Statehouse. Email: sobko@ This article originally appeared on NJ students can visit 9/11 Memorial & Museum for free
Yahoo
21-05-2025
- Health
- Yahoo
Vulnerable people urged to have Covid booster jab
The NHS in Somerset has said only 30% of vulnerable people eligible for a spring Covid-19 vaccination booster have taken up the offer. Since 1 April, 53,000 jabs have been given across the county, but there are fears around low uptake in groups of people who have weakened immune systems. The NHS said those in that group, including people who are having chemotherapy or have conditions such as HIV, are at a significantly higher risk from Covid-19. Mike Kelly, who runs the vaccine programme for the NHS in Somerset said: "We are concerned that many people who need the vaccine most are missing out." More news stories for Somerset Listen to the latest news for Somerset He added: "Whether you've been immunosuppressed and vaccinated for the past few years or were only recently diagnosed with cancer, you are entitled to a Covid-19 vaccination. It's essential protection, and it's easy to access." Dr Bharat Pankhania, a senior lecturer in disease control, said immunisation is more important in vulnerable groups because of a lack of "immune memory". "We have a large number of people who are vulnerable to the effects of the infection... some of them could become very ill. "Repeated infections of the virus, research shows, is harmful. It creates an inflammatory response and it shows they have decline - they have effects on their heart, their blood vessels, and other organs. "Covid-19 does not make good immune memory - you need to be topped up regularly with the vaccine." Follow BBC Somerset on Facebook and X. Send your story ideas to us on email or via WhatsApp on 0800 313 4630. More appointments for patients amid £1m boost NHS Somerset urges those eligible to get Covid jab
BBC News
21-05-2025
- Health
- BBC News
NHS Somerset urges vulnerable people to have Covid booster jab
The NHS in Somerset has said only 30% of vulnerable people eligible for a spring Covid-19 vaccination booster have taken up the 1 April, 53,000 jabs have been given across the county, but there are fears around low uptake in groups of people who have weakened immune NHS said those in that group, including people who are having chemotherapy or have conditions such as HIV, are at a significantly higher risk from Kelly, who runs the vaccine programme for the NHS in Somerset said: "We are concerned that many people who need the vaccine most are missing out." He added: "Whether you've been immunosuppressed and vaccinated for the past few years or were only recently diagnosed with cancer, you are entitled to a Covid-19 vaccination. It's essential protection, and it's easy to access."Dr Bharat Pankhania, a senior lecturer in disease control, said immunisation is more important in vulnerable groups because of a lack of "immune memory"."We have a large number of people who are vulnerable to the effects of the infection... some of them could become very ill."Repeated infections of the virus, research shows, is harmful. It creates an inflammatory response and it shows they have decline - they have effects on their heart, their blood vessels, and other organs."Covid-19 does not make good immune memory - you need to be topped up regularly with the vaccine."
Yahoo
15-05-2025
- Business
- Yahoo
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025 Vancouver, British Columbia--(Newsfile Corp. - May 15, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuro-reparative therapeutics, today reported its financial and operational results for the first quarter ended March 31, 2025. "We continue to make important progress in the clinical development of our lead candidate, NVG-291, in spinal cord injury ("SCI")," said Mike Kelly, NervGen's President and Chief Executive Officer. "Most notably, the last subject in the chronic cohort of our Phase 1b/2a clinical study of NVG-291 for individuals with SCI completed their last visit and we anticipate a topline data readout for this cohort in early June 2025. The subacute cohort continues to actively enroll participants. This important proof-of-concept study is aimed at demonstrating for the first time the potential of NVG-291 in enabling repair of nervous system damage in individuals with SCI and we look forward to sharing the results from the chronic cohort in a few weeks." "Also in the first quarter, the FDA informed us that an expanded access protocol for NVG-291 may proceed. The protocol submission was in response to a request from a physician for expanded access to NVG-291 for a subject who participated in the chronic cohort of the Phase 1b/2a clinical trial," continued Mr. Kelly. Operational Highlights for Q1 2025 We advanced the clinical development of NVG-291: In January 2025, we announced the completion of enrollment in the chronic cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with SCI. Topline data results from the chronic cohort are expected in early June 2025. In February 2025, we announced that the first subject was enrolled and dosed in the subacute cohort of our Phase 1b/2a clinical trial of NVG-291 in individuals with SCI. We also announced that we received IRB approval for an amendment focused on the subacute cohort of our Phase 1b/2a clinical trial. Key changes to the protocol were implemented to facilitate enrollment, for example, revising the timing of subacute SCI to 20 to 90 days post-injury, and to decrease the burden on study participants by reducing the number of visits and assessments. In March 2025, we announced the initiation of an expanded access policy to allow treatment use of the investigational product NVG-291 for those individuals with SCI who have participated in NervGen clinical trials and meet specific eligibility criteria. We received a request from a physician for expanded access to NVG-291 for a subject who participated in the chronic cohort of the Phase 1b/2a clinical trial. After we submitted an expanded access protocol for NVG-291 to the FDA, the FDA informed us that the study could proceed. We advanced our research activities related to our drug candidates: On April 3, 2025, we announced that our pipeline candidate, NVG-300, showed promising activity in preclinical models of ischemic stroke and SCI, suggesting that further investigation is warranted and that preclinical validation in amyotrophic lateral sclerosis ("ALS") will not proceed at this time. Validation of NVG-300 is expected to provide strategic value as a potential partnering asset and/or as a pipeline asset for investigation in additional indications. We continued to strengthen and add expertise to our team with the following additions and appointments: We added senior level talent to support our clinical operations, program management, regulatory affairs, and corporate development. At our Annual General Meeting on May 6, 2025, all of our current directors were re-elected to serve for the following year. Financial Highlights for Q1 2025 Cash and Investments: NervGen had cash and investments of $14.5 million as of March 31, 2025, compared to $17.3 million as of December 31, 2024. The net cash burn for Q1 2025 from operating activities was approximately $4.1 million. This was offset by approximately $1.3 million in net proceeds from our ATM program and warrant exercises. Subsequent to quarter end, we have received a further approximately $2.5 million in net proceeds from warrant and option exercises and our ATM program. R&D Expenses: Research and development expenses were $3.1 million for the three months ended March 31, 2025, compared to $3.0 million in the same period in 2024. The increase in the three months ended March 31, 2025, is primarily related to higher compensation related expenses, including non-cash stock-based compensation expense, as a result of increased headcount to support our CMC, program management, planning and research initiatives. Higher headcount related costs were partially offset by lower clinical and regulatory costs as the chronic cohort nears completion. G&A Expenses: General and administrative expenses were $2.9 million for the three months ended March 31, 2025, compared to $2.0 million for the same period in 2024. The increase in the three months ended March 31, 2025, is primarily related to higher compensation related expenses, including non-cash stock-based compensation expense, reflecting our commitment to attracting and retaining top talent through expanded headcount and competitive compensation packages. Additionally, expenses were higher due to increased investor and public relations activities in Q1 2025, including fees to consultants and costs associated with investor conferences as we ramp up these activities in advance of our upcoming chronic cohort data readout. Net Loss: For the three months ended March 31, 2025, net loss was $3.9 million, or $0.06 per basic and diluted common share. The net loss for the quarter included $1.5 million of non-cash expenses pertaining to amortization, stock-based compensation, and unrealized foreign exchange offset by a $2.0 million non-cash gain due to the fair value adjustment of the warrant derivative. For the three months ended March 31, 2024, net loss was $2.3 million, or $0.04 per basic and diluted common share which included $1.3 million of non-cash expenses pertaining to depreciation, amortization, stock-based compensation, and unrealized foreign exchange offset by a $2.4 million non-cash gain due to the fair value adjustment of the warrant derivative. About Phase 1b/2a TrialThe double-blind, placebo-controlled proof-of-concept Phase 1b/2a clinical trial (NCT05965700) evaluates the safety and efficacy of NVG-291 in two separate cohorts of individuals with cervical motor incomplete spinal cord injury: chronic (1-10 years post-injury) and subacute (20-90 days post-injury), given demonstrated efficacy in preclinical models of both chronic and acute spinal cord injury. The trial is designed to evaluate the safety and efficacy of a fixed dose of NVG-291 using electrophysiological and MRI imaging measures, functional clinical outcome measures, and blood biomarkers that together will provide comprehensive information about the extent of recovery of somatic and autonomic function post-injury. Specifically, the primary objective seeks to assess changes in corticospinal connectivity of defined upper and lower extremity muscle groups following treatment, based on changes in motor evoked potential amplitudes. Secondary objectives evaluate changes in multiple clinical outcome assessments focusing on motor function, upper extremity dexterity, grasping and immobility, and additional electrophysiological measurements. The cohorts will be comprised of 20 subjects each and will be evaluated independently in a blinded manner as the data becomes available. The trial is being partially funded by a grant from Wings for Life, which is being provided in several milestone-based payments and will offset a portion of the direct costs of this clinical trial. More information about participation in the subacute study is available at About NVG-291NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. These studies implicated several potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA for the advancement of NVG-291 in individuals with spinal cord injury. About NervGenNervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical test of concept evaluation of our pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information, visit and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company. Contacts Huitt Tracey, Investor Relationshtracey@ Bill Adams, Chief Financial Officerinfo@ Christy CurranSam Brown Healthcare Communicationschristycurran@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements and information herein include but are not limited to, the company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with SCI; the potential access to NVG-291 through the company's expanded access policy; the development plans, timelines, expected benefits, and prospective target indications for NVG-300; the expected contributions from the added senior level talent; the receipt of the milestone-based grant payments; and the creation of neuro-reparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
